Moreover, treatment of monocytes from B-cell non-Hodgkin lymphoma patients with IL-10 has been shown to decrease human leucocyte antigen–DR isotype (HLA-DR) levels and increase their suppressive capabilities [69]. This evidence concerns the gene IL10 and B-cell non-Hodgkin lymphoma.